Drug discovery deals built around interesting biological targets as opposed to specific disease indications are more likely to spring surprises in terms of their therapeutic direction. Thus, Boehringer Ingelheim may have gotten less than it hoped for when it partnered with Isis Pharmaceuticals Inc. to develop inhibitors of cell adhesion targets. ISIP likewise found itself less than ideally partnered for commercialization of the treatment that emerged from their work.

Last week